Answers are grounded in this paper and cite their sources.
Background Solid organ transplantation (SOT) is an effective therapy for end-stage organ failure; however, long-term postoperative immunosuppression, while preventing graft rejection, impairs immune defense and increases susceptibility to postoperative infection, a common complication and major contributor to morbidity and mortality in SOT recipients. Infection risk is closely related to the type, dose, and duration of immunosuppressive therapy and varies across transplanted organs because of differences in immunogenicity and clinical tolerability. Methods We used data from the Scientific Registry of Transplant Recipients (SRTR) across multiple transplant types to assess associations between immunosuppressants and all-cause overall survival using Kaplan-Meier analysis, the log-rank test, and Cox regression, and to evaluate associations between immunosuppressant exposure and an SRTR-derived binary indicator of infection recorded during available follow-up. Results Postoperative recipients with an infection recorded, as captured in SRTR follow-up reporting, was associated with higher mortality and lower overall survival across SOT types. Associations between specific immunosuppressants and infection differed across transplant types. Tacrolimus was associated with lower odds of recorded infection after liver (OR: 0.83; 95% CI: 0.76-0.91; P < 0.001) and heart transplantation (OR: 0.91; 95% CI: 0.87-0.95; P < 0.001), but higher odds after kidney transplantation (OR: 1.58; 95% CI: 1.45-1.73; P < 0.001). Sirolimus was associated with higher odds of recorded infection after heart (OR: 1.23; 95% CI: 1.07-1.42; P = 0.00454), lung (OR: 1.80; 95% CI: 1.28-2.57; P < 0.001), and kidney transplantation (OR: 1.41; 95% CI: 1.19-1.66; P < 0.001). Conclusion Post-transplant infection recorded during follow-up in this SRTR-based analysis was associated with reduced long-term survival in SOT recipients, and associations between specific immunosuppressants and infection varied by transplant type. These registry-based findings are hypothesis-generating and are not intended to directly inform clinical immunosuppressive decision-making, but may help prioritize candidate agents and regimen patterns for validation in future studies using time-stamped clinical trajectories and causal-inference designs.
No takes yet. Share an insight, caveat, or question.
An et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: